S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV Melanoma
- 1 June 1999
- journal article
- melanoma
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (6) , 1891
- https://doi.org/10.1200/jco.1999.17.6.1891
Abstract
PURPOSE: Monitoring advanced malignant melanoma, serum levels of S100-beta (S100β) and melanoma-inhibiting activity (MIA) were assessed for the ability to discriminate progressive from nonprogressive disease. S100β and MIA were supposed to be superior to conventional variables, such as lactate dehydrogenase (LDH) level. PATIENTS AND METHODS: Seventy-one patients with stage IV malignant melanoma according to the criteria of the American Joint Committee on Cancer (AJCC) were included in the study. Results of restaging examinations were used as an independent reference standard for diagnosing progressive disease, and S100β, MIA, LDH level, and erythrocyte sedimentation rate (ESR) were determined in venous blood just before restaging. Sensitivities and specificities of the parameters were calculated by logistic regression analysis. Discrimination ability was assessed by Somers' Dxy rank correlation and the area under the receiver-operating characteristic curve (ROC-AUC). RESULTS: All tested serum parameters were significantly elevated in patients with progressive disease. The highest sensitivities according to the established thresholds were found for S100β and MIA (91% and 88%, respectively). LDH had the highest specificity (92%). ESR was dropped from the analysis because of low specificity. In calculating Somers' Dxy and ROC-AUC values, S100β, MIA, and LDH showed high discrimination ability. By multiple logistic regression, LDH was identified to be the only statistically significant marker for progressive disease. S100β and MIA did not provide additional significant information because of their high correlation with LDH with respect to clinical outcome. CONCLUSION: Elevated serum levels of S100β, MIA, and LDH indicate current disease progression in AJCC stage IV melanoma. LDH was the most relevant overall parameter.Keywords
This publication has 21 references indexed in Scilit:
- S-100β-Protein im Serum als Tumormarker beim malignen MelanomDie Dermatologie, 1999
- S100 protein serum levels in cutaneous malignant melanoma.Oncology Reports, 1998
- Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanomaBritish Journal of Dermatology, 1997
- Prognostic value of serum analyses of S-100β protein in malignant melanomaMelanoma Research, 1996
- Structure and Promoter Analysis of the Gene Encoding the Human Melanoma-inhibiting Protein MIAPublished by Elsevier ,1996
- Clinical significance of serum S100 in metastatic malignant melanomaEuropean Journal Of Cancer, 1995
- Melanoma-associated antigensEuropean Journal Of Cancer, 1993
- Purification and analysis of growth regulating proteins secreted by a human melanoma cell lineMelanoma Research, 1992
- S100 protein is present in cultured human malignant melanomasNature, 1980
- A soluble protein characteristic of the nervous systemBiochemical and Biophysical Research Communications, 1965